Salvage radiation

RADIATION2 trials

Sponsors

Dana-Farber Cancer Institute, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Esophageal Cancer Stage IVbEsophageal Neoplasm MetastaticProstate Cancer

Phase 2

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Active, not recruitingNCT03141671

Dana-Farber Cancer InstituteProstate Cancer

Start: 2017-11-24End: 2025-12-31Updated: 2024-05-14

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

RecruitingNCT06084897

Cancer Institute and Hospital, Chinese Academy of Medical SciencesEsophageal Cancer Stage IVb, Esophageal Neoplasm Metastatic

Start: 2023-10-16End: 2028-10-26Target: 120Updated: 2024-06-14

Related Papers

Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP).

Journal of Clinical Oncology2024-01-291 citations

FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP).

Journal of Clinical Oncology2023-02-2025 citations

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).

2019-06-135 citations